Skip to main content
Clinical Trials/ACTRN12613000551796
ACTRN12613000551796
Recruiting
Phase 2

In women diagnosed with localised breast cancer, does Accelerated Partial Breast Irradiation (APBI) demonstrate acceptable general cosmesis with an improved quality of life?

Dr Yaw Chin.0 sites60 target enrollmentMay 16, 2013

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Dr Yaw Chin.
Enrollment
60
Status
Recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 16, 2013
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Dr Yaw Chin.

Eligibility Criteria

Inclusion Criteria

  • a) Females more than 50 years of age.
  • b) Performance status 0\-2\.
  • c) Unicentric, invasive ductal carcinoma measuring 3cm in maximal diameter or less.
  • d) Negative surgical resection margins, defined as no tumour at the inked margins.
  • e) No extensive intraductal component, as defined by \>25% of the invasive ductal tumour being comprised of intraductal carcinoma or ductal carcinoma in\-situ being also present in the adjacent breast tissue.
  • f) No lymphovascular invasion.
  • g) No cutaneous involvement, including Paget’s disease of the nipple, oedema (peau d’orange) or inflammatory carcinoma.
  • h) No axillary nodal involvement on sentinel node biopsy or axillary nodal dissection.
  • i) No distant metastases.
  • j) A clearly defined surgical excision cavity and a planning target volume to whole breast volume ratio of \>25%, based on the postoperative CT scan.

Exclusion Criteria

  • a) Locally recurrent breast cancer.
  • b) History of concurrent or previous malignancies (except for non\-melanomatous skin cancer or carcinoma in\-situ of the uterine cervix).
  • c) Her\-2 receptor positive tumours.
  • d) Microscopic assessment of tumour resection margins cannot be defined accurately.
  • e) Women who are pregnant or lactating.
  • f) Pre\-existing connective tissue disorder such as scleroderma, systemic lupus erythematosis and dermatomyositis.
  • g) Patients with ipsilateral breast implants.
  • h) Previous radiation treatment to the ipsilateral breast or thoracic region.
  • i) Psychiatric or addictive disorders that preclude patients from giving informed consent.

Outcomes

Primary Outcomes

Not specified

Similar Trials